To investigate the suitability of FAAH/AEA as a novel sleep-promoting therapeutic target in PS19 Tauopathy/AD mice models, we selectively targeted AEA via the acute and sustained administration of the FAAH inhibitor compound PF3845 and measured sleep phenotypes. The gene discussed is FAAH; the disease is Alzheimer disease.